Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice
J. B. Soriano, J. Vestbo, N. B. Pride, V. Kiri, C. Maden, W. C. Maier (Middlesex, Greenford, Stockley Park, London, United Kingdom; Copenhagen, Denmark)
Source: Annual Congress 2001 - Treatment of COPD in general practice
Session: Treatment of COPD in general practice
Session type: Oral Presentation
Number: 2385
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. B. Soriano, J. Vestbo, N. B. Pride, V. Kiri, C. Maden, W. C. Maier (Middlesex, Greenford, Stockley Park, London, United Kingdom; Copenhagen, Denmark). Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice. Eur Respir J 2001; 16: Suppl. 31, 2385
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Survival in COPD patients after regular use of fluticasone propionate and salmeterol Source: Eur Respir J 2003; 21: 559-560 Year: 2003
Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006
Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice Source: Eur Respir J 2002; 20: 819-825 Year: 2002
Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Effect of discontinuation of inhaled fluticasone propionate on exacerbations in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 183s Year: 2001
Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
Efficacy and safety of ciclesonide compared with fluticasone propionate or budesonide in adolescent patients with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 458s Year: 2007
Efficacy of high-dose inhaled fluticasone propionate in Indian patients having moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002
Long-term clinical management with the salmeterol/fluticasone propionate combination, fluticasone propionate and sameterol in a 'real-life' study Source: Eur Respir J 2003; 22: Suppl. 45, 236s Year: 2003
Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001
Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use Source: Eur Respir J 2004; 24: Suppl. 48, 289s Year: 2004
Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Improvements in FEV1 and symptoms in poorly-reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003
Budesonide and formoterol in a single inhaler quickly gains asthma control compared with fluticasone propionate in mild asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004